Penumbra (PEN) Stock Price, News & Analysis

Company Overview

Penumbra, Inc. is a medical technology company that develops and markets devices for treating vascular conditions. Its products are used in neurovascular procedures, including the treatment of ischemic stroke and aneurysms, and in peripheral vascular procedures involving conditions such as pulmonary embolism and deep vein thrombosis.

The company’s offerings include aspiration and mechanical thrombectomy systems, embolization coils, and related catheter-based devices. Penumbra was founded in 2004 and is headquartered in Alameda, California. It serves customers in the United States and international markets.

Co-founder Adam Elsesser serves as Penumbra’s chairman and chief executive officer.

Key Stats

• Today's Range: $320.63 to $322.00
• 50-Day Range: $316.64 to $325.27
• 52-Week Range: $274.55 to $362.41
• Volume: 237,595 shs
• Average Volume: 396,666 shs
• Market Capitalization: $12.65 billion
• P/E Ratio: 81.21
• Dividend Yield: N/A
• Price Target: $367.07
• Consensus Rating: Hold

Penumbra Stock Analysis - MarketRank™

Penumbra scored higher than 37% of companies evaluated by MarketBeat, and ranked 708th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.6 / 5
• Analyst Rating: Hold

Consensus Rating

Penumbra has received a consensus rating of Hold. The company's average rating score is 2.18, and is based on no strong buy ratings, 3 buy ratings, 14 hold ratings, and no sell ratings.

Upside Potential

Penumbra has a consensus price target of $367.07, representing about 14.4% upside from its current price of $320.96.

Amount of Analyst Coverage

Penumbra has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 23.39%

Earnings Growth

Earnings for Penumbra are expected to grow by 23.39% in the coming year, from $4.96 to $6.12 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Penumbra is 81.21, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.11.

Price to Earnings Ratio vs. Sector

The P/E ratio of Penumbra is 81.21, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.61.

Price to Book Value per Share Ratio

Penumbra has a P/B Ratio of 7.99. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.28% of the float of Penumbra has been sold short.

Short Interest Ratio / Days to Cover

Penumbra has a short interest ratio ("days to cover") of 5.29.

Change versus previous month

Short interest in Penumbra has recently increased by 6.21%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Penumbra does not currently pay a dividend.

Dividend Growth

Penumbra does not have a long track record of dividend growth.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: N/A

News Sentiment

Penumbra has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Healthcare companies.

Search Interest

Only 1 people have searched for PEN on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

2 people have added Penumbra to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Penumbra insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.90% of the stock of Penumbra is held by insiders.

Percentage Held by Institutions

88.88% of the stock of Penumbra is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 10/29/2026
• Today: 11/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NYSE:PEN
• CIK: 1321732
• Web: www.penumbrainc.com
• Phone: (510) 748-3200
• Fax: 510-748-3232
• Employees: 4,700
• Year Founded: 2004

Price Target and Rating

• Average Price Target for Penumbra: $367.07
• High Price Target: $388.00
• Low Price Target: $320.00
• Potential Upside/Downside: +14.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.18
• Research Coverage: 17 Analysts

Profitability

• EPS (Trailing Twelve Months): $3.97
• Trailing P/E Ratio: 81.21
• Forward P/E Ratio: 52.44
• P/E Growth: N/A
• Net Income: $177.69 million
• Net Margins: 10.06%
• Pretax Margin: 13.32%
• Return on Equity: 10.39%
• Return on Assets: 8.09%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 5.89
• Quick Ratio: 3.92

Sales & Book Value

• Annual Sales: $1.40 billion
• Price / Sales: 9.01
• Cash Flow: $4.30 per share
• Price / Cash Flow: 74.62
• Book Value: $40.18 per share
• Price / Book: 7.99

Miscellaneous

• Outstanding Shares: 39,410,000
• Free Float: 38,271,000
• Market Cap: $12.65 billion
• Optionable: Optionable
• Beta: 0.71